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Abstract
Background: Leaf extracts of Scoparia dulcis, is used as a herbal remedy by diabetics worldwide. Fresh Scoparia
dulcis porridge elicited a low glycaemic index (GI) and anti-hyperglycaemic effects when fed to diabetic Wistar rats.
Commercially produced Scoparia dulcis porridge (SDC) elicited medium GI. Present study was aimed at studying the
anti-diabetic effects of consumption of commercially produced S. dulcis porridge.
Method: A randomized crossover clinical trial with type 2 diabetic patients (n = 35) on medication, with mild and
moderate diabetes [fasting blood glucose (FBG) 126–300 mg/dL, age 35–70 years] was conducted. Within the first
three months (study period 1) group 1 was the test and group 2 was the control. Following a wash-out period, the
two groups were crossed over (study period 2: group 1 – control; group 2 - test). Test group consumed commercially
produced SDC for 3 days/week for three months and the control group any other food. At the onset and end of each
study period glucose measurements [Fasting Blood Glucose (FBG), HbA1c], lipid measurements (total cholesterol,
HDL-C, LDL-C, triglycerides, cholesterol ratios), toxicity parameters (liver enzymes, creatinine, CRP, eGFR) were analyzed
by enzyme assay kit methods using a KONELAB 20XT auto analyzer. Significances between groups were analyzed by
one way ANOVA (normal distribution) and Mann Whitney test (if the values were not normally distributed). Within
group comparisons were carried out by Bonferroni post hoc test.
Results: During the crossover clinical trial HbA1c of group 1 decreased from 7.9 ± 0.5 to 6.5 ± 0.3 (p = 0.003) while
HbA1c of group 2 decreased from 7.0 ± 0.3to 6.7 ± 0.3 while in the test group. Therefore, both test groups (1 and 2)
elicited a decrease in HbA1c compared to respective control groups. Both test groups elicited a non significant
decrease in FBG following the intervention (group 1 - from 174 ± 14 to 160 ± 10 mg/dL; group 2 - from 183 ± 13 to
160 ± 7 mg/dL). No significant differences (p >0.05) in insulin, cholesterol measurements (total cholesterol, LDL-C,
HDL-C, triglycerides and cholesterol ratios) and atherogenic index between or within groups were observed. All other
measurements (AST, ALT, ALP, creatinine, CRP, eGFR) were normal and not significantly different between or within
groups.
Conclusion: Porridge made with SDC leaf extract decreased FBG and HbA1c (p >0.05) of type 2 diabetic patients. The
porridge had no effect on cholesterol measurements and no toxicity was observed at the dose tested. Therefore, the
SDC porridge can be recommended as a suitable meal for diabetic patients.
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Background
The global exponential growth of diabetes has led to a
concurrent rise in the usage of herbal remedies to treat
diabetes due to their natural origin, free availability and
lesser side effects [1]. Among the 21,000 herbs listed by
the World Health Organization (WHO) as herbal rem-
edies, only 150 species are utilized in preparation of
large scale commercial herbal products [1]. Scoparia
dulcis is used as a herbal remedy by diabetics worldwide
with proven hypoglycaemic effects [2]. Products such as
tablets and tea made from this herb are currently avail-
able in the international market [3, 4]. However, food
products incorporating the herb are not thus far com-
mercially available.
Rice based herbal porridges (kola kenda) are a common
mode of ingesting herbal extracts in Sri Lanka. Herbal
extracts used for these porridges have proven anti-
hyperglycaemic and anti-hyperlipidaemic effects [2, 5, 6].
Porridges are more palatable and fulfilling compared to a
mere water extract of herbs or tablets and could be
ingested as a meal. A previous study with selected por-
ridges proved that most of these porridges [rice: leaves:
scraped coconut kernel in 25: 15: 10 (w/w/w) ratio] elicit
low glycaemic index (GI) values in normal subjects [7]. A
three month study with streptozotocin induced diabetic
Wistar rats produced a significantly high (p <0.05) weight
gain (opposing the catabolic action/ weight loss in dia-
betes), decreased HbA1c and diabetes related symptoms
(polyuria, low activity rate etc.) in rats fed a diet made
with Scoparia dulcis (SDC) porridge [8]. These effects
were observed when the dried leaf solid dose was 200 mg/
kgBW/day. Further, marked decreases in fasting blood
glucose and urine sugar, with an increase in body weight
had been observed in streptozotocin induced diabetic rats
at a Scoparia dulcis extract dose of 250 mg/kgBW twice a
day for 3 weeks [2]. Leaf extract of S. dulcis also increase
binding of insulin to receptors, insulin synthesis and re-
lease of insulin from beta cells by stimulating Ca2+ influx
[9]. Administration of Scoparia dulcis (200 mg/kgBW) ex-
tract to diabetic rats for 6 weeks, caused a significant reduc-
tion in serum and tissue cholesterol, triglycerides, free fatty
acids, phospholipids, 3-hydroxy-3-methylglutaryl (HMG)-
CoA reductase activity, very low-density lipoprotein and
low-density lipoprotein cholesterol. The decreased serum
high-density lipoprotein cholesterol, anti-atherogenic index,
and HMG-CoA reductase activity in diabetic rats also
returned to normal levels with the treatment [10]. The
SDC porridge was developed as a commercial product tar-
geting diabetic patients as ‘ready to use’ foods are gaining
popularity among the urban populations where the preva-
lence of diabetes is high. The commercially produced por-
ridge had the same ingredient ratio as the porridge used for
previous studies on GI and diabetic Wistar rats and elicited
medium GI in diabetics and in healthy adults due to the
processing rice is subjected to during extrusion [7]. In the
present study, the effects of long term consumption of
commercially prepared Scoparia dulcis porridge on gly-
caemic, lipidaemic measurements and liver and kidney in
type 2 diabetic patients were analyzed.
Methods
Preparation of the extruded meal and porridge
Tender leaves of Scoparia dulcis (15 kg), scraped coco-
nut kernel (10 kg) and red rice [272 6B, Rice Research
Institute, Bombuwala, Sri Lanka] (15 kg) were mixed
and extruded at 110 –120 °C using JR 600 Extruder
(InstraPor). Extruded meal was dehydrated using a hot
air dryer (60–75 °C, 4–5 h). Dried meal was grinded
using a Hammer mill (particle size 100 % pass through
0.5 mm mesh). Extruded meal was mixed in 1:1 ratio
with boiled and dried intact rice grains [7]. Porridge was
packed (40 g) in air tight packets which contained fresh
leaves: rice: scraped coconut kernel in 13–15: 25–30:
10–13 (w/w/w) ratio.
Clinical trial
A randomized crossover study was conducted in the
Department of Biochemistry, Faculty of Medical Sciences,
University of Sri Jayewardenepura, Sri Lanka. Patients were
recruited from the Diabetes clinic of the Family Practice
Centre, University of Sri Jayewardenepura. Minimum re-
quired sample size was 35 in each group. Sample size was
Table 1 Demographic data of the study population
Number 35
Age 35–70 years
Mean age 53.6 ± 7.9 years
Disease Type 2 diabetic patients [mild and moderate




Weight 44 – 101.5 kg
Height 1.38 – 1.73 m
BMI 20 – 33
Waist circumference 79 – 128 cm
Waist circumference
above normal
Females 100 %; males 64 %
Hip circumference 83 – 127 cm
W:H ratio above normal Females 100 %; males 64 %
Total cholesterol 115 – 357 mg/dL
Fasting blood glucose 127 – 302 mg/dL
Obesity percentage Females 87 %; males 58 %
Hypercholesterolaemia 61.5 %
Hypertriglyceridaemia 59.0 %
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calculated using n = 2 k σ2/Δ2 (comparing two means) by
considering mean HbA1c change of 5 % from a mean of
8.0 (, with a SD of 0.6 (, k of 7.8 at 80 % power and 5 % two
sided test (http://trials.slctr.lk/trials/104).
Type 2 diabetic patients, aged 35–70 years, with mild
and moderate diabetes (FBG 126 – 300 mg/dL), who
were not currently using Scoparia dulcis extract/ por-
ridge were selected to participate in the study (Table 1).
Patients with microvascular complications [diabetic retin-
opathy (background diabetic retinopathy/pre proliferative
or proliferative retinopathy/maculopathy/mixed retinop-
athy), macular oedema, diabetic nephropathy (persistent
albuminuria (>300 mg/day or >200 μg/min) that is con-
firmed on at least 2 occasions 3–6 months apart, progres-
sive decline in the glomerular filtration rate (GFR), elevated
arterial blood pressure (above 110–120/70–90 Hgmm),
renal failure confirmed by a physician, diabetic neuropathy],
macrovascular complications [patients who have experi-
enced of a stroke or myocardial infarction or both at least
once, patients who have been recommended for bypass sur-
geries, patients with non-healing wounds, gangrenes or
amputated limbs/ toes], type 1 diabetics, who refused con-
sent, and/or speak only Tamil were excluded from the
study.
Study participants (n = 37) were grouped randomly in to
test (group 1) (Scoparia dulcis) and control (group 2)
groups (17–20/group) (every other patient from a list was
included in to one group by the researchers). Each patient
was in the test group for 3 months and in the control group
for another 3 months. Test group was advised to consume
one packet of Scoparia dulcis porridge once a day for
3 days/ week for 3 months and control group was advised
to consume a normal breakfast except a green leafy por-
ridge. One patient from the test group discontinued partici-
pation due to a hypoglycaemic attack subsequent to
consuming the porridge. Following commencement of the
study, one patient from the control group left the country.
At the end of three months (study period 1) the groups
were crossed over following a washout period of two weeks
and the study was repeated for another three months (study
period 2) with no dropouts. Thus the analyses included 35
patients (Flow diagram 1) (Fig. 1).
Fig. 1 Flow diagram 1 study design
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Blood (8 cc) were drawn from the median cubital vein
of the patients (fasted for 8 – 10 h), by a trained phle-
botomist, at the onset and end of each month during the
study and serum was separated by centrifuging the sam-
ples at 3500 rpm. Liver enzymes (AST, ALT, ALP), cre-
atinine, urea, CRP, lipid measurements (total cholesterol,
LDL, HDL and TG) and blood glucose measurements
(fasting blood glucose, HbA1c, insulin) were measured
at the onset and at the end of the third month of the
study. All parameters were measured by enzymatic kit
assays (BIOLABO, France) except for plasma insulin
which was measured by an ELISA assay (DRG Diagnos-
tics Insulin assay kit). eGFR was calculated using the
standard equation [186 x (creatinine/88.4)-1.154 x (Age)-
0.203 x (0.742 if female) x (1.210 if black)]. All analyses
were carried out on the same day that the blood samples
were collected. Considering the cost and practical diffi-
culties, the week 12 values of insulin and HbA1c were
considered as unchanged and taken as the basal values
for the second study period (week 14).
Ethical approval
Ethical approval for the study was obtained from the Ethics
Review Committee of the Faculty of Medical Sciences,
University of Sri Jayewardenepura, Nugegoda (Approval
No. 632/12). Written consent was obtained after explaining
the study procedure to each volunteer prior to
commencement of the study. The trial was registered with
the Sri Lanka Clinical Trials Registry (SLCTR) (Registration
No. SLCTR/2012/011).
Statistical analysis
Significances of data of the clinical trial between groups
were analyzed by one way ANOVA (normal distribution)
and Mann Whitney test (if the values were not normally
distributed). If the data do not violate the sphericity
(Mauchly's test), significant differences between the
means within groups at different time points were ana-
lyzed by one way repeated measures ANOVA. If the data
violated sphericity, the presence of overall significant dif-
ferences was identified by Greenhouse-Geisser correc-
tion. A p value <0.05 for Greenhouse-Geisser indicates a
significant difference in means within groups. For such
groups, within group comparisons were carried out by
Bonferroni post hoc test to infer which means differed at
different time points. Statistical analysis was carried out
using SPSS version 16.
Results
The study group consisted of 12 males and 23 females
and mean age of participants was 53.6 ± 7.9 years. All
the patients were residents of Colombo District, West-
ern province, Sri Lanka. In the present study group 56 %
and 34 % of patients have had diabetes for 1–10 years
Table 2 Glycaemic parameters of groups 1 and 2
Study period 1 Study period 2
FBG (mg/dL) Test (mean ± SEM) Control (mean ± SEM)
0 week 12 weeks 14 weeks 26 weeks
Group 1a 174 ± 14 160 ± 10 199 ± 15 192 ± 19
Control (mean ± SEM) Test (mean ± SEM)
0 week 12 weeks 14 weeks 26 weeks
Group 2b 166 ± 11 171 ± 9 183 ± 13 160 ± 7
HbA1c (%) Test (mean ± SEM) Control (mean ± SEM)
0 week 12 weeks 14 weeks 26 weeks
Group 1a 7.9 ± 0.46 6.5 ± 0.30a 6.5 ± 0.30 7.1 ± 0.39
Control (mean ± SEM) Test (mean ± SEM)
0 week 12 weeks 14 weeks 26 weeks
Group 2b 7.6 ± 0.36 7.0 ± 0.31 7.0 ± 0.31 6.7 ± 0.24
Insulin (IU/L) Test (mean ± SEM) Control (mean ± SEM)
0 week 12 weeks 14 weeks 26 weeks
Group 1a 12.2 ± 10.4 14.9 ± 8.0 14.9 ± 8.0 12.1 ± 10.0
Control (mean ± SEM) Test (mean ± SEM)
0 week 12 weeks 14 weeks 26 weeks
Group 2b 16.6 ± 3.5 12.3 ± 1.5 12.3 ± 1.5 10.4 ± 1.2
Week 0 and week 14 indicates the basal serum parameters as those values have been obtained prior to the intervention
an = 16, bn = 19; SEM = standard error of mean; Superscripts indicate a significant difference in a parameter when compared to basal value within a study
period (p <0.05)
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Table 3 Total cholesterol, triglycerides, LDL, HDL concentrations (mg/dL), total cholesterol: LDL, total cholesterol: HDL and LDL: HDL
ratios of groups 1 and 2
Study period 1 Study period 2
TC (mg/dL) Test (mean ± SEM) Control (mean ± SEM)
0 week 12 weeks 14 weeks 26 weeks
Group 1a 228 ± 12 235 ± 13 246 ± 10 224 ± 10
Control (mean ± SEM) Test (mean ± SEM)
0 week 12 weeks 14 weeks 26 weeks
Group 2b 211 ± 14 233 ± 10 224 ± 14 232 ± 11
TG (mg/dL) Test (mean ± SEM) Control (mean ± SEM)
Group 1a 0 week 12 weeks 14 weeks 26 weeks
123 ± 9 139 ± 15 182 ± 20 175 ± 23
Control (mean ± SEM) Test (mean ± SEM)
Group 2b 0 week 12 weeks 14 weeks 26 weeks
142 ± 15 185 ± 15 171 ± 16 164 ± 19
LDL (mg/dL) Test (mean ± SEM) Control (mean ± SEM)
Group 1a 0 week 12 weeks 14 weeks 26 weeks
163 ± 11 168 ± 11 169 ± 10 151 ± 8
Control (mean ± SEM) Test (mean ± SEM)
Group 2b 0 week 12 weeks 14 weeks 26 weeks
137 ± 14 152 ± 9 147 ± 11 153 ± 10
HDL (mg/dL) Test (mean ± SEM) Control (mean ± SEM)
Group 1a 0 week 12 weeks 14 weeks 26 weeks
39.5 ± 2.1 39.0 ± 1.8 40.3 ± 1.9 37.3 ± 2.0
Control (mean ± SEM) Test (mean ± SEM)
Group 2b 0 week 12 weeks 14 weeks 26 weeks
43.9 ± 2.8 42.5 ± 2.1 42.8 ± 2.8 44.8 ± 2.3
Study Period 1 Study Period 2
TC:LDL Test (mean ± SEM) Control (mean ± SEM)
0 week 12 weeks 14 weeks 26 weeks
Group 1a 1.43 ± 0.04 1.49 ± 0.05 1.42 ± 0.03 1.47 ± 0.03
Control (mean ± SEM) Test (mean ± SEM)
0 week 12 weeks 14 weeks 26 weeks
Group 2b 1.63 ± 0.06 1.56 ± 0.03 1.56 ± 0.05 1.55 ± 0.04
TC:HDL Test (mean ± SEM) Control (mean ± SEM)
0 week 12 weeks 14 weeks 26 weeks
Group 1a 6.28 ± 0.40 5.69 ± 0.50 3.95 ± 0.28 4.20 ± 0.32
Control (mean ± SEM) Test (mean ± SEM)
0 week 12 weeks 14 weeks 26 weeks
Group 2b 5.22 ± 0.54 5.62 ± 0.34 5.50 ± 0.38 5.53 ± 0.43
LDL:HDL Test (mean ± SEM) Control (mean ± SEM)
0 week 12 weeks 14 weeks 26 weeks
Group 1a 4.33 ± 0.35 4.28 ± 0.28 6.29 ± 0.39 5.89 ± 0.37
Control (mean ± SEM) Test (mean ± SEM)
0 week 12 weeks 14 weeks 26 weeks
Group 2b 3.38 ± 0.48 3.69 ± 0.28 3.62 ± 0.32 3.71 ± 0.36
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and more than 10 years respectively. Changes observed
in mean glycaemic measurements of groups 1 and 2 dur-
ing the study period are indicated in Table 2.
When considering the two study periods [study period
1 (0–12th week), study period 2 (14th–26th week)], the
initial (0 week and 14th week) FBG between groups 1
and 2 were not significantly different (p = 0.63, p = 0.42).
Although not significant, FBG in both test groups de-
clined following the intervention (Table 2) when com-
pared to the controls.
During the two study periods, initial (0 week and 14th
week) HbA1c between group 1 and 2 were not signifi-
cantly different (p = 0.89, p = 0.31). However, a signifi-
cant decrease (p = 0.003) in HbA1c in group 1 was
observed during the intervention. In group 2 a signifi-
cant decline in HbA1c was not observed (p = 0.98).
Mean serum insulin levels were not significantly differ-
ent (p >0.05) between or within group 1 and group 2
during both the study periods.
Lipid measurements
Table 3 indicates the changes in serum cholesterol mea-
surements of the two groups during the study period.
There was no significant difference (p >0.05) in any of
the lipid parameters (TC, LDL-C, TG and HDL-C)
within groups 1 and 2 during both study periods. How-
ever, the TG in group 2 (control) was significantly higher
when compared to group 1 (test) (p = 0.036) at the end
of first 3 months (study period 1). A significantly high
(p = 0.022) HDL-C level was observed in the test group
(group 2) compared to the control (group 1) at the end
of the second 3 months (study period 2). TC and LDL-C
were above the upper limit of normal and TG was near
the upper limit of normal in groups 1 and 2 during both
study periods.
Estimation of TC: HDL, also known as atherogenic or
Castelli index and LDL: HDL are vital indicators of car-
dio vascular risk [11] as they indicate the imbalance be-
tween the cholesterol carried by atherogenic and
protective lipoproteins. Total cholesterol and TG per se
do not provide details on accurate risk levels, mainly in
familial hypercholesterolaemia [12] (Real et al.). There-
fore, to identify the risk level of the study population,
total cholesterol: LDL, total cholesterol: HDL and LDL:
HDL ratios of the groups 1 and 2 at study periods 1 and
2 were calculated (Table 3). However, no significant dif-
ference was observed between or within the groups 1
and 2 at any study period.
Although serum total cholesterol (TC) is normal, with
low HDL level, the probability of development of athero-
sclerotic plaque is high [13]. As TC per se or HDL per se
will not provide a clear picture regarding the risk of
atherogenicity, atherogenic index (AI = log TC/HDL)
was assessed. Atherogenic index of >0.21 indicates a
high risk of atherosclerosis [14] (Table 3). However, no
significant difference (p >0.05) between or within the
groups 1 and 2 was observed for AI at any study period
of the study.
Toxicity measurements
Table 4 indicates the AST, ALT, ALP, creatinine, urea
and CRP values in the test and control groups during
the two study periods. A significant difference (p >0.05)
was not observed between or within the two groups for
all tested liver enzymes. Mean measurement variations
of liver enzymes were within the normal reference range
during both study periods (1 and 2). Mean eGFR of all
study participants was within the normal range and was
between 74.2 – 87.5 mL/min/1.73 m2, irrespective of the
duration of diabetes (<1 year; 1–10 years; >10 years). No
significant change was observed in urea, creatinine and
CRP during both study periods.
Discussion
This clinical trial was designed to investigate the antidia-
betic potential and toxic effects of consumption of a
novel commercially produced herbal porridge in dia-
betics. The dried leaf solid dose in the porridge (per
serving 35 mg/kgBW; 3 packets/week; 15 mg/kgBW/
day) was 13–33 times lower than the doses (250 – 500 mg/
kgBW) used in previously reported studies [2]. Despite the
lower leaf dosage used in porridge, a reduction in FBG was
Table 3 Total cholesterol, triglycerides, LDL, HDL concentrations (mg/dL), total cholesterol: LDL, total cholesterol: HDL and LDL: HDL
ratios of groups 1 and 2 (Continued)
AI Test (mean ± SEM) Control (mean ± SEM)
0 week 12 weeks 14 weeks 16 weeks
Group 1a 0.49 ± 0.05 0.54 ± 0.06 0.61 ± 0.06 0.64 ± 0.7
Control (mean ± SEM) Test (mean ± SEM)
0 week 12 weeks 14 weeks 16 weeks
Group 2b 0.50 ± 0.06 0.62 ± 0.04 0.59 ± 0.05 0.54 ± 0.06
Week 0 and week 14 indicates the basal serum parameters as those values have been obtained prior to the intervention
an = 16, bn = 19; SEM = standard error of mean; Superscripts indicate a significant difference in a parameter when compared to basal value within a study
period (p < 0.05)
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observed in both test groups during study periods 1 (per-
centage reduction = 8 %) and 2 (percentage reduction =
13 %) compared to the two control groups. This indicates
that even a low dose of S. dulcis leaves as used in this study
could elicit significant anti-hyperglycaemic effects. A 1 %
reduction of HbA1c over three months is known to reduce
the risk of micro-vascular complications by 37 %, DM re-
lated complications and death by 21 % [15]. As there was a
significant decrease (1.4 %; p = 0.003) in HbA1c in group 1
during the intervention and a non-significant (0.3 %; p =
0.98) decline in HbA1c in group 2, consumption of SDC
porridge may contribute towards a reduction of micro-
Table 4 AST, ALT, ALP, creatinine, urea and CRP measurements of groups 1 and 2
Study period 1 Study period 2
AST(IU/L) Test (mean ± SEM) Control (mean ± SEM)
0 week 12 weeks 14 weeks 26 weeks
Group 1a 36.7 ± 4.7 37.0 ± 2.4 51.6 ± 5.6 41.4 ± 3.4
Control (mean ± SEM) Test (mean ± SEM)
0 week 12 weeks 14 weeks 26 weeks
Group 2b 32.5 ± 2.6 40.3 ± 4.3 39.0 ± 2.2 47.5 ± 4.1
ALT(IU/L) Test (mean ± SEM) Control (mean ± SEM)
0 week 12 weeks 14 weeks 26 weeks
Group 1a 43.3 ± 5.7 39.0 ± 3.7 55.5 ± 8.1 41.2 ± 8.9
Control (mean ± SEM) Test (mean ± SEM)
0 week 12 weeks 14 weeks 26 weeks
Group 2b 37.0 ± 4.7 42.6 ± 3.8 44.5 ± 5.3 43.0 ± 5.5
ALP(IU/L) Test (mean ± SEM) Control (mean ± SEM)
0 week 12 weeks 14 weeks 26 weeks
Group 1a 214 ± 19 231 ± 13a 232 ± 13 233 ± 12
Control (mean ± SEM) Test (mean ± SEM)
0 week 12 weeks 14 weeks 26 weeks
Group 2b 258 ± 14 329 ± 24b 330 ± 24 281 ± 20c
Study period 1 Study period 2
Creatinine (mg/dL) Test (mean ± SEM) Control (mean ± SEM)
0 week 12 weeks 14 weeks 26 weeks
Group 1a 0.85 ± 0.04 0.93 ± 0.06 1.00 ± 0.05 0.90 ± 0.05a
Control (mean ± SEM) Test (mean ± SEM)
0 week 12 weeks 14 weeks 26 weeks
Group 2b 0.75 ± 0.03 0.92 ± 0.03b 0.91 ± 0.03 0.91 ± 0.03
Urea (mmol/L) Test (mean ± SEM) Control (mean ± SEM)
0 week 12 weeks 14 weeks 26 weeks
Group 1a 4.2 ± 0.34 4.1 ± 0.55 5.5 ± 0.64 3.4 ± 0.28a
Control (mean ± SEM) Test (mean ± SEM)
0 week 12 weeks 14 weeks 26 weeks
Group 2b 4.5 ± 0.33 4.1 ± 0.24 4.2 ± 0.30 3.6 ± 0.18
CRP (mg/dL) Test (mean ± SEM) Control (mean ± SEM)
0 week 12 weeks 14 weeks 26 weeks
Group 1a 3.3 ± 0.74 3.4 ± 0.79 3.8 ± 1.05 3.0 ± 0.58
Control (mean ± SEM) Test (mean ± SEM)
0 week 12 weeks 14 weeks 26 weeks
Group 2b 4.3 ± 1.03 5.1 ± 0.88 5.1 ± 0.88 6.0 ± 1.11
Week 0 and week 14 indicates the basal serum parameters as those values have been obtained prior to the intervention
an= 16; bn= 19; SEM= standard error of mean; Superscripts indicate a significant difference in a parameter when compared to basal value within a study period (p< 0.05)
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vascular and other fatal complications in diabetics [15].
Thus continuous consumption of S. dulcis porridge may
help in reducing the morbidity and mortality due to
diabetes.
A significant change in mean plasma insulin was not ob-
served between or within the groups 1 and 2 indicating that
there was no change in insulin synthesis, secretion or bind-
ing to receptors during the study period when the patients
were in the control group. However, a decrease in FBG and
HbA1c in both test groups during both study periods
(study periods 1 and 2) was observed. This could be due to
an increment of both the insulin level (synthesis and secre-
tion) and binding to receptors mediated by SDC [9] or
might be due to other mechanisms. Some mechanism
attributed to consumption of Scoparia dulcis leaf extract in-
clude decreased oxidative stress in RINm5F pancreatic cells
[16], increased glucose uptake by increased GLUT4 expres-
sion, translocation and activity [17], decreased glucose 6-
phosphatase and fructose 1, 6-bisphosphatase enzymes [18]
and increased hexokinase, glucose 6-phosphate dehydro-
genase and glycogen synthase enzymes [18]. In this study a
significant decrease in TC, TG and LDL-C concentrations
were not observed as in previous studies [10], which could
be due to the lower amount of active compounds in the
porridge (35 mg/kgBW).
The study also revealed that 61.5 % and 59.0 % of the
study population was hypercholesterolaemic and/or hyper-
triglyceridaemic respectively. More than 80 % of the T2DM
patients in this study belonged to the high risk category ac-
cording to the atherogenic index indicating a high suscepti-
bility of these patients for cardio-vascular diseases.
An elevated occurrence in lipid abnormalities in pa-
tients who have had diabetes for more than one year
was observed during this study. The percentages of hy-
percholesterolaemic and hypertriglyeridaemic diabetic
patients were 82.7 % and 90.5 % respectively. Insulin re-
sistance elevates the VLDL and apolipoprotein (apo) B-
containing lipoproteins concurrently diminishing the
suppressive effect of insulin on apo B secretion either by
reducing apoB degradation or by inhibition of micro-
somal TG transfer protein activity [19]. This highlights
the importance of regular assessment and appropriate
goal directed management of lipid parameters once dia-
betes is diagnosed.
Absence of any significant elevation of AST, ALT, ALP,
creatinine or urea or a decline in eGFR in both test
groups compared to control during both study periods
(study period 1 and 2), indicate that there is no acute or
short term liver or kidney toxicity by consumption of
the porridge at the dose given. Further studies are rec-
ommended to prove the effects of consumption of SDC
porridge continuously for a long period.
CRP is an inflammatory marker and is generally ele-
vated in diabetic patients [20]. As CRP is also an active
participant of atherogenesis, there is a high risk of the
occurrence of cardio-vascular diseases in diabetics [21].
There was no elevation of CRP in both the test groups
during study period 1 and 2 compared to control. This
suggests that SDC porridge does not contribute to elicit
inflammatory reactions.
Precision of the results could have been increased with
a higher number of patients, however due to the limited
time period this could not be achieved. As the study was
not a double blinded study and as the control group had
not received a placebo, existence of bias to a certain ex-
tent in the present study is possible.
Conclusion
Porridge made with Scoparia dulcis leaf extract reduce
fasting blood glucose and HbA1c levels without elevat-
ing liver enzymes, creatinine, urea and CRP in type 2
diabetic patients. As a rice based herbal porridge is more
palatable and fulfilling than a leaf extract or a tablet, the
porridge used for this study would be a better breakfast
meal for diabetics due to its medium GI [7], anti-
hyperglycaemic effects and absence of toxicity. Diabetic
patients should also be made aware regarding the im-
portance of controlling their lipid parameters.
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